334 related articles for article (PubMed ID: 27160747)
21. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection.
Stalenhoef JE; van Nieuwkoop C; Wilson DC; van der Starre WE; van der Reijden TJK; Delfos NM; Leyten EMS; Koster T; Ablij HC; van 't Wout JJW; van Dissel JT
BMC Infect Dis; 2019 Feb; 19(1):161. PubMed ID: 30764769
[TBL] [Abstract][Full Text] [Related]
22. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
23. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
24. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
[TBL] [Abstract][Full Text] [Related]
25. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
[TBL] [Abstract][Full Text] [Related]
26. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study.
van Oers JAH; Kluiters Y; Bons JAP; de Jongh M; Pouwels S; Ramnarain D; de Lange DW; de Grooth HJ; Girbes ARJ
J Crit Care; 2021 Dec; 66():173-180. PubMed ID: 34340901
[TBL] [Abstract][Full Text] [Related]
27. Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD.
Citgez E; Zuur-Telgen M; van der Palen J; van der Valk P; Stolz D; Brusse-Keizer M
Chest; 2018 Jul; 154(1):51-57. PubMed ID: 29475034
[TBL] [Abstract][Full Text] [Related]
28. Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study.
Viaggi B; Poole D; Tujjar O; Marchiani S; Ognibene A; Finazzi S
PLoS One; 2018; 13(8):e0201491. PubMed ID: 30102716
[TBL] [Abstract][Full Text] [Related]
29. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
Elke G; Bloos F; Wilson DC; Brunkhorst FM; Briegel J; Reinhart K; Loeffler M; Kluge S; Nierhaus A; Jaschinski U; Moerer O; Weyland A; Meybohm P;
Crit Care; 2018 Mar; 22(1):79. PubMed ID: 29562917
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
31. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
[TBL] [Abstract][Full Text] [Related]
32. MR-proAdrenomedullin as a predictor of renal replacement therapy in a cohort of critically ill patients with COVID-19.
Roedl K; Jarczak D; Fischer M; Haddad M; Boenisch O; de Heer G; Burdelski C; Frings D; Sensen B; Karakas M; Kluge S; Nierhaus A
Biomarkers; 2021 Jul; 26(5):417-424. PubMed ID: 33754916
[TBL] [Abstract][Full Text] [Related]
33. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review.
Cavallazzi R; El-Kersh K; Abu-Atherah E; Singh S; Loke YK; Wiemken T; Ramirez J
Respir Med; 2014 Nov; 108(11):1569-80. PubMed ID: 25448309
[TBL] [Abstract][Full Text] [Related]
34. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
[TBL] [Abstract][Full Text] [Related]
35. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak RM; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng LL; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Hartmann O; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2011 Aug; 58(10):1057-67. PubMed ID: 21867843
[TBL] [Abstract][Full Text] [Related]
36. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
Schuetz P; Litke A; Albrich WC; Mueller B
Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
[TBL] [Abstract][Full Text] [Related]
38. Correlation of inflammatory and cardiovascular biomarkers with pneumonia severity scores.
Lacoma A; Bas A; Tudela P; Giménez M; Mòdol JM; Pérez M; Ausina V; Dominguez J; Prat-Aymerich C
Enferm Infecc Microbiol Clin; 2014 Mar; 32(3):140-6. PubMed ID: 24054971
[TBL] [Abstract][Full Text] [Related]
39. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study.
Dres M; Hausfater P; Foissac F; Bernard M; Joly LM; Sebbane M; Philippon AL; Gil-Jardiné C; Schmidt J; Maignan M; Treluyer JM; Roche N
Int J Chron Obstruct Pulmon Dis; 2017; 12():1047-1056. PubMed ID: 28408815
[TBL] [Abstract][Full Text] [Related]
40. Mid-Regional Proadrenomedullin and Mid-Regional Proatrial Natriuretic Peptide Clearance Predicts Poor Outcomes Better Than Single Baseline Measurements in Critically Ill Patients With Pneumonia: A Retrospective Cohort Study.
Van Oers J; Krabbe J; Kemna E; Kluiters Y; Vos P; De Lange D; Girbes A; Beishuizen A
Cureus; 2021 May; 13(5):e15285. PubMed ID: 34221750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
